December 2016
-
Swiss spray-drying specialist Micro-Sphere and Singapore-based NanoMaterials Technology (NMT) have announced a new technology partnership to provide development and manufacturing services. The companies say that Micro-Sphere will contribute its emulsification and spray drying technology to… Read more . . .
-
Sandoz has received German marketing authorization for the AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD, the company has announced. The German approval is for the 50/500 µg version of the inhaler.… Read more . . .
-
GlaxoSmithKline and Theravance have announced that Canadian regulators approved the Anoro Ellipta umeclidinium/vilanterol DPI for the treatment of COPD on December 23, 2013, shortly after the US FDA approved the product. The dosage approved for… Read more . . .
-
MannKind Corporation has announced that a meeting of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee for a review of the company’s NDA for Afrezza insulin inhalation powder has been scheduled tentatively for April 1,… Read more . . .
-
The FDA’s Nonprescription Drugs Advisory Committee and Pulmonary Allergy Drugs Advisory Committee (PADAC) will meet on February 25, 2014 to consider a new drug application submitted by Armstrong Pharmaceuticals for an OTC epinephrine inhalation aerosol… Read more . . .
-
Iliad Biotechnologies has licensed technology from Institut Pasteur de Lille, Inserm, National University of Singapore, and National University of Ireland Maynooth related to a live attenuated Bordetella pertussis vaccine, and the company says that it… Read more . . .
-
Civitas Therapeutics has announced the appointment of former MAP Pharmaceuticals CEO Timothy S. Nelson as Chairman of the board of directors. Nelson commented, “Civitas has a highly-validated drug inhalation platform, a potentially transformative Parkinson’s therapy… Read more . . .
-
Forest Laboratories has agreed to pay $2.9 billion cash for Aeroquin developer Aptalis. Aeroquin inhaled levofloxacin for the treatment of P. aeruginosa infections in CF patients, which is in Phase 3 development, was acquired by… Read more . . .
-
Aerogen and Philips have announced an agreement that “includes the acquisition of select assets solely related to Aerogen’s home-care business” by Philips. The announcement appears to refer to Aerogen’s Aeroneb Go vibrating mesh nebulizer. Philips… Read more . . .
-
Advocacy organization Allergy & Asthma Network Mothers of Asthmatics (AANMA) has announced that Tonya Winders will take over as Chief Executive Officer as of January 1, 2014. She succeeds founder Nancy Sander, who retired in… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland